Principal Investigator: Dr Anto Rajamani

The study aims to recruit participants diagnosed with dementia with Lewy Bodies and age and gender matched participants with Alzheimers disease (AD) and those with no cognitive impairment.

Summary

The BBDLB study is a cross sectional study comprising of a single visit at the participants home, care home or at the Clinical Research Facility at QMC.

The study aims to recruit participants diagnosed with dementia with Lewy Bodies and age and gender matched participants with Alzheimers disease (AD) and those with no cognitive impairment.

Purpose

Investigating RNA profiles of plasma SEV, enriched for neuronal and microglial origin, to improve understanding of the molecular pathology underlying neurodegeneration in DLB and identify key RNA molecules for facilitating the discovery of reliable diagnostic biomarkers and potential therapeutic targets for DLB.

Primary Objective

To identify differentially expressed RNA in plasma SEV, enriched for neuronal and microglial origin, of people living with DLB.

Main Inclusion Criteria

• Patients diagnosed to have either DLB or AD
• Patient without any mental health diagnosis and have been clinically diagnosed NOT to have dementia, MCI, or PD will be eligible to be recruited in the comparison group.
• Participants lacking capacity with a personal consultee.

Study duration: Three years - 01/10/2022 to 30/09/2025

Per participant: One cross-sectional assessment without any follow-up. The assessment questionnaires are completed within 45-60 minutes and 30 ml of venous blood is collected from each participant.

Funding: This study is funded by the Innovate UK

Contacts: For more information please contact Sue Smith, Senior Research Delivery Officer at This email address is being protected from spambots. You need JavaScript enabled to view it. or 07920 453 824.